Ep. 227: The Impact of Environmental Factors on Parkinson's Disease Burden: Perspectives, Risks, Opportunities

Show notes

Moderator: Paolo Ragonese (Cefalù, Italy)

Guest: Alexis Elbaz (Paris, France)

In this episode, Paolo Ragonese speaks with Alexis Elbaz about environmental risk factors and their contribution to the burden of Parkinson’s disease. They discuss epidemiological approaches to identifying relevant exposures, including pesticides, solvents and air pollution, as well as the role of lifestyle factors, with a focus on modifiable risks, disease prevention, and early recognition.

Show transcript

00:00:00: Welcome to EANcast, your weekly source for education research and updates from the European Academy of Neurology.

00:00:15: Good morning everyone!

00:00:17: This is new EAN cast episode.

00:00:21: The title of this actual episode about the impact on environmental factors on Parkinson's disease pattern perspective rates & no opportunities.

00:00:33: This is about how to apply epidemiological methods in the study of neurodegenerative disease.

00:00:40: Here's Paolo Ragonesi speaking, I'm Associate Professor of Neurology at Sencamille Lucio International University in Rome and today we are very happy as a speaker professor Alexis Elbadz.

00:00:56: Professor Alexis Eladzis is a Research Professor in Epidemiology.

00:01:00: He is practising neurology to specialise in moving disorders, particularly at the San Petrero Hospital which I imagine you can all know very well.

00:01:15: In particular, the epidemiology of Parkinson's disease was one of the main focuses on his research and he has coordinated several large-scale epidemiological studies in particular in Parkinson's Disease in examining environmental exposure for this disease And this is also in charge at present.

00:01:36: In the wide court studies, which are called E-TRIEN on Parkinson's disease epidemiology a court comprising over one hundred thousand persons, women in particular that have been recruited since their nineties and has been followed up ever since.

00:01:57: So Alexis once again to have accepted this invitation to participate, join us today and I ask you to introduce the topic of the day.

00:02:09: Thank You!

00:02:10: Thank you very much Professor Ragonese.

00:02:12: so it's a pleasure to be with you today to talk about environmental risk factors and Parkinson disease some challenges and opportunities from recent studies.

00:02:24: i would like to ask you something first of all.

00:02:27: recently Global Barter of Disease studies about Parkinson's raised up the question that even though GPD talked about a Parkinson pandemic describing global increase in the barter disease, the incidence seems to be quite stable over time.

00:02:50: So can you explain us what does this mean?

00:02:55: Thank you.

00:02:56: So, your right the global burden of disease has shown that a number of PD patients so that is prevalence as increased over the past years quite rapidly.

00:03:07: for instance The Number Of Parkinson's Disease Patients Worldwide Has Increased From Two Point Five Millions In Ninety-Ninety to Twelve Millions in Twenty-Twenty and this Is Of Course Expected To Continue To Increase.

00:03:22: What's important to understand is that prevalence is determined by incidence.

00:03:26: That is the number of new cases that occur each year, but also by disease duration and ascertainment of the patient.

00:03:34: so because PD incidents increases sharply with age The main driver of increase in the numbers of PD patients Is population aging due To a larger number Of persons at risk Each Year.

00:03:51: So, we have also shown that longer disease duration contributes to increase the number of PD patients because PD patients just live longer.

00:03:59: And so this means not only there will be more patients in future years but they'll still be severe and require a second-line treatment for example.

00:04:10: There's attention on the health system as in parallel the number is not increasing.

00:04:17: It's also possible, in addition to what I said about aging and a longer disease duration that environmental exposures have changed over the years.

00:04:25: could play your role.

00:04:27: But this has not been clearly demonstrated And In fact as you've said once we account for age incidence of Parkinson diseases is rather stable Over time or even slightly decreases decreased in some countries where it had been studied.

00:04:43: However, also what's important to understand is that incidence has been mainly studied in higher income countries and there's really a lack of data.

00:04:52: In many countries particularly lower-income countries.

00:04:55: so because it such an important increase the number of PD patients then we still have no cure for Parkinson disease.

00:05:02: That why its' important try identify preventive strategies which could help prevent or at least delay the onset of Parkinson's disease.

00:05:11: And so this is why it's so important to better understand which factors are associated with PD incidence and we could modify.

00:05:18: Thank

00:05:19: you, thank you.

00:05:19: This very interesting increase our understanding about things are evolving.

00:05:27: One difficult that emerged from all these studies performed Is in particular for diseases like Parkinson's Disease It is difficult to investigate And to understand the impact of several environmental risk factors, why it is so difficult.

00:05:45: So you're right and I think there are several reasons... ...and i think this one of most important messages to communicate.. ..is that identification on risk factors of Parkinson's disease or other diseases such as dementia for example raise a number of challenges.

00:06:02: So the first is that Parkinson's, as they mentioned develops very slowly over many years and has a long program phase.

00:06:11: That can be as long as twenty years or more in some patients.

00:06:16: so if environmental exposures are other risk factors contribute to the disease The relevant exposure may have occurred then twenty or even thirty years before the clinical diagnosis.

00:06:28: It means we really need information about the people's environment over very long periods, and so we need to do a lot of studies.

00:06:38: So this is for example one interest in large cohort study such as Etrian which you mentioned or Framingham cohort that follow persons many years.

00:06:50: then they can look at exposures based on the incidence of disease.

00:06:56: ten-twenty-thirty.

00:06:59: It's also important, this long-programmed phase because it can lead to something that we call reverse causation.

00:07:06: Reverse causation is the situation in which disease affects exposure years before a disease occurs.

00:07:15: for example in Parkinson's disease we know that constipation is very common in the prodromal phase of the Parkinson's disease, even ten or twenty years later.

00:07:26: It's possible that consti-patient may affect their way people eat so diet and if you're looking at diet with PD incidence this means really need to look at diet before the prodromal symptoms occur.

00:07:39: So I think that's one very important issue to consider when we look at the risk factors of Parkinson disease.

00:07:51: Another difficulty is that Parkinson disease, as you know it's mainly a clinical diagnosis and even very experienced neurologists can make errors in their diagnoses And ascertainment of Parkinson diseases.

00:08:04: in large studies The reference approach is to do some kind of screening and then have someone examine the patients, confirm their diagnosis.

00:08:14: This is what it's usually done in door-to-door studies but this is very difficult or very expensive even impossible to do.

00:08:22: for example administrative databases.

00:08:26: More and more frequently, we're using algorithms to diagnose Parkinson's disease in these databases.

00:08:31: And this algorithm of course are associated with some risk of misclassification... ...and it is really important that you take into account when looking at the studies I think.

00:08:41: third another difficulty is measuring exposure is difficult.

00:08:45: for many historical exposures We don't have individual measurements so we have to reconstruct the exposure from residential history occupation use models, etc.

00:08:57: And this is one difficulty also related to these issues.

00:09:01: that of course Parkinson's disease multifactorial disorder and exposures don't tend to occur in isolation so they usually are combined with other exposures has led to the concept of the exposome, so that really instead of looking at one exposure at a time now more and more we're trying to look at combination of exposures that could be associated with.

00:09:29: And then finally, I think another difficulty is that Parkinson's disease is a heterogeneous disease.

00:09:35: There are these apoptices of the brain first and body-first forms of the diseases... ...and it's possible there may be different biological pathways for this disorder.

00:09:46: so this is another difficult to look at risk factors in Parkinson's diseases.

00:09:51: So an environment with quite wide concept can mean interpreted in several ways, but moving from the methodological part to more practical aspects.

00:10:04: In your opinion or starting with data you obtained on your studies which environmental exposures are currently considered as major concerns related to Parkinson's disease?

00:10:19: Well I think it really depends how we define our environment so that I will take more a broader definition.

00:10:27: So if we really look at what can consider environmental exposures, I think pesticides have been very well studied in Parkinson's disease since many years now and this was the sort of accidental finding that persons exposed to MPTP developed Parkinsonism and MPTP is similar to a pesticide called Paraqua very often used, and this triggered these studies on the relation between pesticides and Parkinson's disease.

00:10:58: And now we've acquired a lot of evidence on the relationship between pesticides in Parkinson's diseases.

00:11:06: It is different if pesticides occur in an occupational setting or they are really more related to where people live In farmers, there's a lot of studies that have shown now that farmers exposed to pesticide are very high risk of Parkinson disease.

00:11:23: The the risk is about sixty-to seventy percent higher in farmers exposed through pesticides and this has even led to the recognition of PD as an occupational disorder in exposed farmers in France since two thousand twelve And I think Germany also just or also has done the same.

00:11:44: so I think the evidence is quite strong.

00:11:48: The main difficulty that we have, it's really to identify which pesticides are involved because farmers often use tans or even... many, many pesticides for many years.

00:12:00: And pesticides also have changed a lot over the time so it's really difficult to disentangle which ones may be more particularly involved and this is where toxicology studies are also useful.

00:12:12: So there some evidence that those that cause oxidative stress mitochondrial dysfunction so Paracwad, Rotenon Also organochlorine insecticides And some carbamate fungicides are the most likely candidates for Parkinson's disease.

00:12:28: So this is in farmers, and these of course led to the question that whether exposure to pesticides in the environment so people who live close to the fields where the pesticides are sprayed at higher risk?

00:12:41: This is a very difficult question to study because we don't have data mostly on what people are exposed.

00:12:47: It can be studied in California with registry of use of pesticides since many years, and there's a very nice studies that have been done in California showing that residential exposure to pesticides is associated with an increased risk for Parkinson disease.

00:13:04: In France we've also done some ecological studies showing the incidence of Parkinson diseases not in farmers so in general population are higher in agricultural regions particularly those grown by carrots.

00:13:19: So I think pesticides are really a very interesting model for Parkinson's disease and the evidence is quite strong.

00:13:28: There's also interesting evidence on solvents now that has been emerging, in particular trichloroethylene.

00:13:34: A very nice study was recently published by Samuel Goldmann and Carly Tanner about the risk of Parkinson disease in marines who have been exposed to trichlaryletylene in their youth... ...and had a higher risk for developing Parkinson diseases.

00:13:50: I think additional studies are needed.

00:13:53: air pollution is also being studied recently with less clear results.

00:14:00: So I think for air pollution, the evidence is not that consistent.

00:14:04: as for Parkinson's disease and of course there are a lot It's very difficult to study air pollution because, of course people who live in more polluted areas may have different characteristics compared to those living less polluted area.

00:14:19: So confounding is an issue.

00:14:21: so I think most studies are needed here.

00:14:24: Head trauma...I don't know if we can consider this as environmental exposure but there some evidence?

00:14:29: But i would like talk a little bit about health behaviors that may be more easily modifiable.

00:14:38: And mainly, in particular I would like to talk about physical activity and nutrition.

00:14:43: so physical activity is not that simple to study in Parkinson's disease because as i said due to this prodromal phase it's possible that persons May reduce their physical activity level in the years before they're going to develop Parkinson's Disease.

00:14:58: but still we have now some nice studies showing Physical activity in midlife, so long time before the diagnosis appears is associated with a reduced risk of Parkinson's disease.

00:15:14: And off course we know that physical activities patients are very important and nutrition again can be affected by reverse causation.

00:15:21: but type of diet, so more vegetables less meat more fish olive oil etc.

00:15:32: have a reduced risk of Parkinson disease.

00:15:36: and then finally there's lot of studies now that are interested in drug repurposing So trying to see if drugs That I used for other indications could be associated with reduce risk or delay In the diagnosis of Parkinson diseases because This could lead to some development for neuroprotective treatment.

00:16:00: So I think this is also an interesting research avenue

00:16:06: Very clear, very exhaustive and give rise too many other patients of course.

00:16:14: For instance the interaction between environmental like you were saying just now the interaction between environmental risk factors and the host, so as human beings.

00:16:27: And our dopaminergic receptor for instance...and so on.. The other consideration that comes to my mind is if there are so relevant environmental exposures they can be modified.

00:16:42: we could act also in planning some strategies to prevent Parkinson's disease.

00:16:48: How can this be done?

00:16:52: So, I think you're right.

00:16:53: This is a very exciting possibility of course and that's what we would all like.

00:16:59: so... We have seen the number of PD patients continues to increase due to population aging even if age standardized incidence are stable or slightly decreases.

00:17:10: these could reflect many things including the reduction in some risk factors to be found or better general health and health behaviors, are also changing diagnosis because you know that in recent years we're more... We can better diagnose Parkinson's disease.

00:17:29: In particular, we can make a difference with the other for most Parkinsonism.

00:17:33: so I think this supports idea.

00:17:35: it may be possible to reduce the burden of PDS as is has been shown by dementia.

00:17:40: So recently we've seen incidents of dementia decreasing.

00:17:45: the number of patients is still increasing due to population aging, but incidence is decreasing.

00:17:52: This represents an important motivation for identifying modifiable risk factors that could be targeted.

00:17:58: and also it's important to improve the detection of pre-symptomatic PD during the prodermal phase in order to target persons at higher risks if we have something that we can intervene on.

00:18:11: So I think that at the present time, physical activity and diet are best candidates.

00:18:17: And this is why i wanted to mention health behaviors before because they have been shown to be associated with PD risk.

00:18:24: They also have preotropic effects on many outcomes.

00:18:26: so we know that physical activities and nutrition are really good for health in general.

00:18:35: easiest way to try to reduce the burden of Parkinson's disease.

00:18:39: It is also reasonable, maybe consider banning some toxic pesticides and improve education in persons who use them if it isn't possible for them.

00:18:48: but its really difficult measure this approach because the impact on the pesticides at a general population level are not that easy to measure And they change so much over time.

00:19:02: the persons who are developing PD now, because they were exposed to pesticides.

00:19:06: These pesticides in many countries have already been banned and it's really new pesticide that is going to be developed right now will have an effect on the future.

00:19:15: so its not very simple but I think yes.

00:19:21: there starting discussions about how to prevent PD.

00:19:25: this goes through better detection of the prodromal phase of PD during the prodermal phase and also trying to identify modifiable risk factors.

00:19:37: Yeah, this is very interesting!

00:19:38: And you accidentally introduced another method or other issues that should deserve probably another complete podcast made in the future because we introduce a problem over intervening moving from treating symptoms of disease to identify high strategies to prevent it, and moving early in life.

00:20:03: To change the way we approach with our health maybe as a whole.

00:20:08: so move into the prodromal phase of diseases to intervene to determine such changes in neurodegeneration trajectories for instance.

00:20:20: but this is quite complex because we should plan to act since we are twenty-five years old or lives maybe?

00:20:29: Yes, so I know there is some clinical trials that start in particular physical activity by the team of Basblom who are targeting persons with REM sleep behavior disorder.

00:20:41: So you need to know that REM sleep behavioral disorder is a prodromal symptom for Parkinson's disease.

00:20:47: it not specific and also associated other conditions.

00:20:51: but People who have RBD are at very high risk of developing neurodegenerative conditions, and they may be the persons in whom you would like to reduce their risks or delay the onset of these disorders.

00:21:08: Thank you again!

00:21:10: We can conclude that epidemiological studies aren't meant just for identifying natural diseases just not meant to identify risk factors but they have a direct possible impact on how to treat, intervene in the earlier phases of disease and as we were saying before on the prodromal phase is to prevent if possible or even slow down the slope of the neurodegenerative processes like in particular diseases happens.

00:21:50: So, this is very interesting in my opinion.

00:21:54: And it's open to news and very impactful, relevant studies that go home.

00:22:02: so once again, we're sorry about as usual It was a pleasure too

00:22:09: Thank you.

00:22:17: This has been EANcast Weekly Neurology.

00:22:19: thankyou for listening.

00:22:21: be sure to follow us on Apple Podcasts Spotify or your preferred podcatcher for weekly updates from the European Academy of Neurology.

00:22:29: You can also listen to this and all of our previous episodes on the EAN campus, To gain points & Become an EAN expert in any of her twenty-nine neurological specialties.

00:22:39: Simply become a EAN individual member to gain access.

00:22:42: For more information visit ean dot org slash membership.

00:22:46: That's E A N Dot O R G Backslash Membership.

00:22:51: Thanks for listening E&Cast weekly.

00:22:54: neurology is your unbiased and independent source for educational, research-related neurological content.

00:23:00: Although all the contents are provided by experts in their field it should not be considered official medical advice.

New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.